Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Immucell Corp changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 25 | 27 | +2 |
| Shares | 1.31M | 1.28M | −28.7K (−2.2%) |
| Value | $9.00M | $8.08M | −$923.3K (−10.3%) |
New holders (4)
Institutions that held Immucell Corp at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Steadtrust LLC | 31,700 | $198.1K | 0.13% |
| Citigroup Inc | 170 | $1.10K | 0.00% |
| Barclays PLC | 7 | $44 | 0.00% |
| Royal Bank of Canada | 1 | $0 | 0.00% |
Sold out (2)
Institutions that held Immucell Corp at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Prosperity Planning, Inc. | 16,000 | $111.4K |
| Raymond James Financial Inc | 1,970 | $13.7K |